Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
Harald Hampel, Sid E. O’Bryant, José Luís Molinuevo, et al.
Nature Reviews Neurology (2018) Vol. 14, Iss. 11, pp. 639-652
Open Access | Times Cited: 555

Showing 1-25 of 555 citing articles:

The Amyloid-β Pathway in Alzheimer’s Disease
Harald Hampel, John Hardy, Kaj Blennow, et al.
Molecular Psychiatry (2021) Vol. 26, Iss. 10, pp. 5481-5503
Open Access | Times Cited: 1058
miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis
Carmen Elena Condrat, Dana Claudia Thompson, Mădălina Gabriela Barbu, et al.
Cells (2020) Vol. 9, Iss. 2, pp. 276-276
Open Access | Times Cited: 1057
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts
Thomas K. Karikari, Tharick A. Pascoal, Nicholas J. Ashton, et al.
The Lancet Neurology (2020) Vol. 19, Iss. 5, pp. 422-433
Open Access | Times Cited: 1008
Alzheimer's disease
José Arguedas López, Hector M. González, Gabriel C. Léger
Handbook of clinical neurology (2019), pp. 231-255
Closed Access | Times Cited: 634
Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration
Elisabeth H. Thijssen, Renaud La Joie, Amy Wolf, et al.
Nature Medicine (2020) Vol. 26, Iss. 3, pp. 387-397
Open Access | Times Cited: 632
Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease
Niklas Mattsson, Nicholas Cullen, Ulf Andréasson, et al.
JAMA Neurology (2019) Vol. 76, Iss. 7, pp. 791-791
Open Access | Times Cited: 580
Current state of Alzheimer’s fluid biomarkers
José Luís Molinuevo, Scott Ayton, Richard Batrla, et al.
Acta Neuropathologica (2018) Vol. 136, Iss. 6, pp. 821-853
Open Access | Times Cited: 445
A multicentre validation study of the diagnostic value of plasma neurofilament light
Nicholas J. Ashton, Shorena Janelidze, Ahmad Al Khleifat, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 387
Lecanemab: Appropriate Use Recommendations
J Cummings, L Apostolova, G D Rabinovici, et al.
The Journal of Prevention of Alzheimer s Disease (2023)
Open Access | Times Cited: 383
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
Harald Hampel, Filippo Caraci, A. Claudio Cuello, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 270
Developing the ATX(N) classification for use across the Alzheimer disease continuum
Harald Hampel, Jeffrey L. Cummings, Kaj Blennow, et al.
Nature Reviews Neurology (2021) Vol. 17, Iss. 9, pp. 580-589
Closed Access | Times Cited: 235
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Thomas K. Karikari, Nicholas J. Ashton, Gunnar Brinkmalm, et al.
Nature Reviews Neurology (2022) Vol. 18, Iss. 7, pp. 400-418
Closed Access | Times Cited: 213
The human connectome in Alzheimer disease — relationship to biomarkers and genetics
Meichen Yu, Olaf Sporns, Andrew J. Saykin
Nature Reviews Neurology (2021) Vol. 17, Iss. 9, pp. 545-563
Open Access | Times Cited: 178
Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays
Kaj Blennow, Leslie M. Shaw, Erik Stomrud, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 167
An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders
Nicholas J. Ashton, Abdul Hye, Anto P. Rajkumar, et al.
Nature Reviews Neurology (2020) Vol. 16, Iss. 5, pp. 265-284
Open Access | Times Cited: 162
Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
Niklas Mattsson, Shorena Janelidze, Randall J. Bateman, et al.
EMBO Molecular Medicine (2021) Vol. 13, Iss. 6
Open Access | Times Cited: 153
Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease
Andrea Vergallo, Lucile Mégret, Simone Lista, et al.
Alzheimer s & Dementia (2019) Vol. 15, Iss. 6, pp. 764-775
Open Access | Times Cited: 147
Retinal imaging in Alzheimer's and neurodegenerative diseases
Peter J. Snyder, Jessica Alber, Clemens Alt, et al.
Alzheimer s & Dementia (2020) Vol. 17, Iss. 1, pp. 103-111
Open Access | Times Cited: 146
Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease
Hong Wang, Kaushik Dey, Ping‐Chung Chen, et al.
Molecular Neurodegeneration (2020) Vol. 15, Iss. 1
Open Access | Times Cited: 141
Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape
Harald Hampel, Yan Hu, Jeffrey L. Cummings, et al.
Neuron (2023) Vol. 111, Iss. 18, pp. 2781-2799
Open Access | Times Cited: 122
Alzheimer’s disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs
Ana Rita Monteiro, Daniel José Barbosa, Fernando Remião, et al.
Biochemical Pharmacology (2023) Vol. 211, pp. 115522-115522
Open Access | Times Cited: 121
Multiplexed immunosensors for point-of-care diagnostic applications
Bruno M. G. Rosa, Oluwatomi E. Akingbade, Xiaotong Guo, et al.
Biosensors and Bioelectronics (2022) Vol. 203, pp. 114050-114050
Open Access | Times Cited: 116
Omics sciences for systems biology in Alzheimer’s disease: State-of-the-art of the evidence
Harald Hampel, Robert Nisticò, Nicholas T. Seyfried, et al.
Ageing Research Reviews (2021) Vol. 69, pp. 101346-101346
Closed Access | Times Cited: 107
Designing the next-generation clinical care pathway for Alzheimer’s disease
Harald Hampel, Rhoda Au, Soeren Mattke, et al.
Nature Aging (2022) Vol. 2, Iss. 8, pp. 692-703
Open Access | Times Cited: 107
Blood-Based Biomarkers for Alzheimer’s Disease Diagnosis and Progression: An Overview
Angelica Varesi, Adelaide Carrara, Vitor Gomes Pires, et al.
Cells (2022) Vol. 11, Iss. 8, pp. 1367-1367
Open Access | Times Cited: 78
Page 1 - Next Page

Scroll to top